BillionToOne published a study showing its Northstar Response blood test predicts survival in advanced solid tumor patients receiving immunotherapy more accurately than standard imaging. The test detects molecular progression earlier by a median of 62 days, allowing doctors to adjust treatment sooner. Combining molecular monitoring with imaging gave the strongest prediction of patient outcomes. This non-invasive test uses serial blood draws and works across multiple tumor types, offering a promising tool for personalized cancer care.
YMCA of Northern Alberta and Capital Power have teamed up to send 600 children to summer camp who otherwise could not afford it. Capital Power's three-year commitment supports access to various YMCA camps and programs that build confidence and commun...
Fidelity Advisor Series VIII has increased its voting rights in Renk Group AG to 3.23% as of June 24, 2026. This includes 3.04% voting rights attached to shares and 0.19% through stock loan instruments. The total voting rights represent a significant...
Fidelity Advisor Series VIII, based in Boston, has raised its voting rights stake in Renk Group AG to 3.23% as of June 24, 2026. This includes 3.04% direct voting rights and 0.19% through stock loan instruments. The total voting rights are based on 1...
CRCAM Toulouse announced that no repurchases of its cooperative investment certificates (CCI) were made during the week of June 22 to June 26, 2026. This update is part of their regular weekly disclosure on CCI transactions, reflecting no activity in...
Security National Financial Corporation announced a 5% stock dividend for shareholders recorded on July 10, 2026, to be issued on July 17, 2026. This marks the company's 38th consecutive year of declaring a stock dividend, reflecting its commitment t...
